Famotidine is one of the most common over the counter and prescription heartburn medications on the market, sold under names like Pepcid and in many store brand versions. Employees preparing for a workplace drug screen sometimes ask whether an H2 blocker like famotidine could trigger a false positive, especially on an amphetamine or methamphetamine panel. The short answer is that there is no published cross reactivity evidence tying famotidine to a false positive immunoassay result. A related, now withdrawn medication called ranitidine has an actual documented history here, and the distinction matters for anyone trying to understand what a screening result can and cannot tell an employer.
What Famotidine Is and How It Differs From Ranitidine
Famotidine and ranitidine are both histamine H2 receptor antagonists, a drug class used to reduce stomach acid production for heartburn, acid reflux, and ulcers. They are chemically related but not identical. According to the DailyMed label for an over the counter famotidine tablet product, famotidine is indicated for relief of heartburn associated with acid indigestion and sour stomach, and the label carries no controlled substance schedule designation. That label is a useful reference point because the drug facts panel and the absence of any Drug Enforcement Administration schedule marking are consistent with famotidine not being a controlled substance.
Ranitidine, sold historically under the brand name Zantac, was also an H2 blocker and was withdrawn from the market after manufacturers found levels of a nitrosamine impurity above the acceptable daily intake limit in many ranitidine containing products. A Federal Register notice from the Food and Drug Administration confirms that manufacturers voluntarily withdrew their ranitidine products from sale for this reason, and that the withdrawal applied broadly across ranitidine formulations. See the Federal Register notice for the agency language on that withdrawal. Famotidine was not part of that action and remains available over the counter and by prescription.
Is Famotidine a Controlled Substance?
No. Famotidine does not appear on any Drug Enforcement Administration controlled substance schedule, and nothing in its DailyMed labeling suggests a scheduling designation. The famotidine drug label describes it as a nonprescription acid reducer with routine over the counter availability, which is not how controlled substances are marketed or labeled. An employee who discloses famotidine use to a medical review officer is not disclosing use of a controlled medication, though documentation is still useful any time a legitimate medication could come up in a conversation about a drug test result.
Could Famotidine Affect a Standard 5, 10, or 12 Panel Immunoassay?
Standard workplace immunoassay panels are built around specific drug classes. A 5 panel typically screens for amphetamines, cannabinoids, cocaine metabolites, opiates, and phencyclidine. Expanded 10 and 12 panel configurations add classes such as barbiturates, benzodiazepines, methadone, methaqualone, and propoxyphene. H2 blockers as a drug class are not one of the analytes or cross reactive classes that panel manufacturers design or validate against, and famotidine specifically has not been identified in published literature as a source of interference on any of these classes.
| Panel class screened | What it targets | Does famotidine fall in this class |
|---|---|---|
| Amphetamines and methamphetamine | Amphetamine, methamphetamine, and related stimulant metabolites | No, famotidine is an H2 receptor antagonist, not a stimulant |
| Cannabinoids | THC metabolites | No |
| Opiates and opioids | Morphine, codeine, and related opioid metabolites | No |
| Cocaine metabolites | Benzoylecgonine | No |
| Phencyclidine | PCP | No |
What the Published Evidence Actually Shows
A study that analyzed electronic health records to identify medications associated with interference on point of care urine drug screening assays tested a range of common medications, including ranitidine, against immunoassay panels. The study found that ranitidine produced a presumptive positive on the methamphetamine assay at a specific spiked concentration, and also produced presumptive positives on opiate and propoxyphene assays at higher concentrations. The full study is available through PubMed Central. That same analysis did not identify or test famotidine as a source of interference on any panel. In plain terms, there is published, peer reviewed evidence of a historical ranitidine and methamphetamine immunoassay interaction, and no published cross reactivity evidence for famotidine on any standard panel. If a lab or test manufacturer later publishes new data on famotidine specifically, that would need to be weighed on its own, but nothing currently available supports treating famotidine as a known interferent.
Why the Ranitidine History Still Comes Up
Because famotidine and ranitidine are both H2 blockers and were once sold for the same purpose, people sometimes assume whatever is true of one is true of the other. That assumption does not hold here. Ranitidine's reported immunoassay interaction and its market withdrawal are two separate facts about one specific molecule, not about the H2 blocker class as a whole. Famotidine has a different chemical structure, and the interference research cited above tested ranitidine directly rather than inferring an effect for the entire drug class. An employee who used to take ranitidine before it left the market and now takes famotidine instead is not carrying over any documented drug test risk.
How GC/MS or LC/MS Confirmation Resolves a Presumptive Positive
Immunoassay screening, whether on a cup, dip card, or oral fluid device, is a presumptive test. It flags specimens that fall above a cutoff concentration for a drug class, and it can occasionally react to structurally similar compounds. It does not identify the exact substance present. Any nonnegative screening result in a regulated or defensible testing program should move to confirmation by gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry. These confirmation methods identify and quantify specific molecules rather than drug classes, which is why a true false positive from an unrelated medication is resolved at this stage rather than at the initial screen. If a specimen screens positive for amphetamines or methamphetamine and the donor has not used methamphetamine, confirmation testing is the mechanism that should show a negative or a result consistent with the actual substance present.
The MRO Review and Prescription Documentation Step
In federally regulated testing programs, a confirmed positive result goes to a medical review officer, a licensed physician trained to interpret drug test results in a clinical context, before it is reported to the employer as verified. Under 49 CFR Part 40, the medical review officer must review the laboratory result, give the donor an opportunity to provide a legitimate medical explanation, and verify any explanation involving a legally prescribed or over the counter medication. Part 40 Subpart G sets out the medical review officer's review duties, and a related section addresses how a medical review officer verifies a claimed prescription or authorization for a medication that could explain a result. That verification process is the formal channel for resolving a disputed result tied to a legitimate medication, and it exists specifically so that common, legal medications are not treated the same as illicit drug use. Non regulated employer programs generally follow a similar review model even when Part 40 does not directly apply, though program rules vary by employer and by state.
What Employers Should Do With a Disputed Result
If an employee reports taking famotidine, an over the counter heartburn medication, and disputes a positive amphetamine or methamphetamine screen, the appropriate response is to route the specimen or the result through confirmation testing and medical review officer evaluation rather than accepting or rejecting the explanation on the spot. Employers should document the conversation, preserve the chain of custody record, and let the confirmation result and the medical review officer's verified determination control the final outcome. Employers should generally avoid making an adverse decision based on a screening result alone, and may want to consult legal counsel on how their drug free workplace policy and any applicable state law apply to a specific case, since requirements vary by state and by industry.
For employers managing their own point of care screening, choosing drug test cups with an integrated amphetamine and methamphetamine panel and pairing that with a lab confirmation pathway for any nonnegative result keeps the process consistent with how these cases are supposed to be resolved. For more on how amphetamine and methamphetamine panels are built and interpreted, see this explanation of AMP and mAMP panel design, and for another common stimulant class cross reactivity question, see this piece on decongestants and methamphetamine false positives.
Frequently asked questions
Does famotidine show up as methamphetamine on a drug test?
There is no published cross reactivity evidence showing famotidine triggers a methamphetamine or amphetamine immunoassay result. Famotidine is chemically distinct from the stimulant compounds those panels are designed to detect.
Is famotidine the same as ranitidine for drug testing purposes?
No. They are both H2 blockers, but only ranitidine has published interference data on a methamphetamine immunoassay, and ranitidine was withdrawn from the market for an unrelated safety reason. Famotidine is a different molecule with no comparable published history.
Is famotidine a controlled substance?
No. Famotidine is not scheduled by the Drug Enforcement Administration and is sold over the counter and by prescription as an acid reducer.
What should an employee do if famotidine use comes up during a drug test review?
Disclose the medication to the medical review officer or testing administrator and be ready to show how it was obtained, such as an over the counter purchase or a pharmacy record, if asked. This is a documentation step, not an admission of anything related to illicit drug use.
How does a lab tell the difference between methamphetamine and an unrelated medication?
Confirmation testing by gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry identifies the specific molecule present in a specimen, rather than reacting to a drug class the way a screening immunoassay does. This is the step that resolves any ambiguity from the initial screen.
Can an employer take action based only on a positive screening result?
Employers should generally route any nonnegative screen to confirmation testing and, where applicable, medical review officer verification before making an employment decision. Policies and legal requirements vary by employer and by state, so employers may want to consult counsel on their specific process.
This article is general information for workplace drug testing programs, not legal or medical advice. Employers and individuals should consult qualified counsel or a medical professional for guidance specific to their situation.
